• Mashup Score: 1

    Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, is an emerging treatment for inflammatory bowel disease (IBD) and is increasingly used in clinical practice. Real-world data suggest clinical efficacy of upadacitinib in nearly 80% of patients.

    Tweet Tweets with this article
    • “This study offers valuable real-world insights into a growing clinical scenario: how to manage #inflammatory bowel disease patients who do not respond to or cannot tolerate #upadacitinib.” #AGAReadingRoom @AmerGastroAssn #Gastroenterology Read more: https://t.co/uzGkyY2jTU https://t.co/02i9M4hzYu